logo
Nestle Q1 preview: What to expect from Kitkat maker in June quarter?

Nestle Q1 preview: What to expect from Kitkat maker in June quarter?

Nestle Q1 results preview: Kitkat and Maggi maker Nestle is scheduled to release its first quarter (Q1FY26) results on Thursday, July 24, 2025. Brokerages reckon Nestle's performance is likely to remain muted amid the inflationary setting across its segments.
Further, a surge in the depreciation, given the commissioning of new capital expenditure and lower other non-operating income, is likely to have a bearing on earnings growth.
Nestle Q1 results 2025: Profit estimates
Brokerages tracked by Business Standard estimate Nestle's net profit to decline 5.6 per cent year-on-year (Y-o-Y) on average, to ₹731.85 crore as compared to ₹775.9 crore. Sequentially, the net profit is expected to fall 17.34 per cent from ₹885.4 crore in Q4FY25.
Nestle Q1 results 2025: Revenue expectations
Here's how brokerages expect Nestle to fare in Q1FY25:
Kotak Institutional Equities: Analysts at the brokerage forecast 6.6 per cent Y-o-Y growth in net revenues, led by 6.5 per cent/7 per cent growth in domestic/exports as against 4.2 per cent/(-)8.7 per cent in Q4FY25.
Consolidated revenue is pegged at ₹5,130.4 crore as compared to ₹4,814 crore a year ago.
Volume (tonnage) is expected to grow at 3 per cent, a slight improvement against 2 per cent in Q4. The gross margin is likely to contract 65 basis points (bps) Y-o-Y to 57 per cent as against 65 bps decline in Q4, impacted by high inflation in coffee, cocoa, milk, wheat and palm oil prices.
Earnings before interest, tax, depreciation and amortisation (Ebitda) is anticipated to grow at 8.1 per cent to ₹1,191.3 crore Y-o-Y as compared to ₹1,102.3 crore and Ebidta margin is pegged at 23.2 per cent, up 30 bps Y-o-Y from 22.9 per cent.
Emkay Global Financial Services: The brokerage sees a 5 per cent topline growth in Q1FY26 to ₹ 5047.5 crore Y-o-Y with 1 per cent volume growth. To negate the inflationary stress, the company has selectively effected price hikes, although Emkay sees price growth to be lower amid increased promotion intensity.
Gross margin is expected to contract 110 bps Y-o-Y to 56.5 per cent. Ebitda margin is likely to see a 70 bps contraction Y-o-Y to 22.2 per cent from 22.9 per cent. Ebitda is likely to grow 2 per cent to ₹1,121.8 crore as compared to ₹1,102.3 crore.
Motilal Oswal Financial Services: Motilal analysts expect Nestle's overall sales to grow 5.7 per cent Y-o-Y, led by 5.5 per cent growth in domestic sales and 10 per cent growth in export sales. However, while demand recovery is underway, a higher dependency on urban markets may weigh on the company's volumes.
The company has most likely implemented a price hike in response to rising commodity prices. Motilal forecasts gross profit margin to contract 60 bps Y-o-Y to 57 per cent, impacted by a rise in raw material prices like coffee and edible oil, while a stable Ebitda margin of 23.3 per cent in Q1FY26 is expected.
Nuvama Institutional Equities: The brokerage reckons consolidated revenue to grow 4.7 per cent Y-o-Y in Q1FY26 to ₹503.87 crore. Domestic sales are likely to grow 4–5 per cent Y-o-Y, while domestic volumes shall grow 2–3 per cent Y-o-Y.
Exports revenue is likely to decrease by 2–3 per cent Y-o-Y. Nuvama expects price hikes of 3 per cent in Q1FY26, mainly led by coffee and premium chocolates.
The company's Ebitda is likely to grow 6.5 per cent Y-o-Y to ₹1,174 crore as compared to ₹1,102.3 crore. Given the benefit of the recent palm oil duty, Nestle's gross/Ebitda margin is expected to improve 115 bps/40 bps Y-o-Y to 56.5 per cent/23.3 per cent. As the urban slowdown tapers down likely by Q2FY26, demand trends are anticipated to further improve hereon.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amid lab-grown rise, Tanishq launches diamond expertise centres
Amid lab-grown rise, Tanishq launches diamond expertise centres

Business Standard

time19 hours ago

  • Business Standard

Amid lab-grown rise, Tanishq launches diamond expertise centres

Amid the growing popularity of lab-grown diamonds, jewellery giant Tanishq has launched three new diamond expertise centres in collaboration with the De Beers Group. These centres aim to provide buyers with clarity and transparency, ensuring value to the customer through a technology-backed evaluation system. "There is a lot of confusion caused by the emergence of lab-grown diamonds, and we expect the prices of lab-grown diamonds to keep decreasing as the technology to create them evolves. More customers are now asking if we're selling natural or lab-grown diamonds, and it is this confusion we want to eliminate," said Ajoy Chawla, Chief Executive Officer (CEO) of the jewellery division at Titan Company. Currently, these centres are located in three stores in Bengaluru, but the company plans to expand them to 200 stores in the ongoing financial year (FY26) and eventually roll them out across all 599 stores nationwide. Commenting on gold prices, Chawla told Business Standard that the surge in gold prices has led to ticket-size driven growth, with diamond-studded jewellery also witnessing increased buyer demand. In its quarterly update to the exchanges in early July, the company reported an 18 per cent growth in its jewellery domestic operations for the first quarter (Q1FY26), which was marked by gold price volatility. The company is also observing a shift towards lightweight and lower caratage jewellery among customers. In response, Tanishq has piloted 9-carat gold jewellery under its Mia brand in several coastal markets to assess the impact of humidity. A Mia official told Business Standard earlier this week that the collection, consisting of 25 offerings, will be fully launched before Diwali. Having become a household name over the past 30 years, Tanishq has catered to over 1.3 crore customers to date, with almost 52 lakh purchasing diamond-studded gold jewellery. Speaking about the US tariffs of 25 per cent imposed on Indian exports, Chawla said, "It's too early to react. We should not get carried away, as these tariffs may change over time."

India's DAP imports from China fall to 97,000 tonnes in July amid new rules
India's DAP imports from China fall to 97,000 tonnes in July amid new rules

Business Standard

timea day ago

  • Business Standard

India's DAP imports from China fall to 97,000 tonnes in July amid new rules

India's import of Di Ammonium Phosphate (DAP) from China has declined sharply and stood at 97,000 tonnes in July this year, Parliament was informed on Friday. DAP is the second most consumed fertiliser after urea in India. Minister of State for Chemicals and Fertilisers Anupriya Patel said DAP import from China declined from approximately 22.28 lakh tonnes in 2023-24 to about 8.47 lakh tonnes in 2024-25 as reported by fertiliser companies. "In July 2025, approximately 0.97 lakh tonnes of DAP have been imported from China," the minister said in a written reply to the Lok Sabha. Phosphatic and Potassic (P&K) fertilisers, including DAP, are under Open General License (OGL). The fertiliser companies are free to import/manufacture these fertilisers as per their business dynamics. Citing reasons for the decline in DAP import, the minister said in October 2021, China amended its catalogue of commodities requiring mandatory additional inspection prior to export of fertiliser-related items, including DAP. The regulatory requirement led to an increase in the CFR (Cost and Freight) price of DAP for India from USD 542 per tonne in April 2024 to approximately USD 800 per tonne in July 2025. The minister said Ammonium Phosphate Sulphate (APS) may serve as a partial alternative to DAP, particularly in sulphur-deficient soils and for sulphur-demanding crops. APS supplies nitrogen, phosphorus, and sulphur, but contains a lower phosphorus content of 20 per cent as compared to 46 per cent in DAP. Thus, APS is a crop- and soil-specific supplement. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally
GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

Business Standard

timea day ago

  • Business Standard

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to ₹279 crore for the June quarter. The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal. Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted. Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at ₹2,898.40 apiece on BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store